Browse the corpus

Efavirenz is an FDA-approved antiretroviral medication introduced in 1998 (and approved for use in the UE in 1999) that has played a pivotal role in the treatment and prevention of HIV. As a member of the non-nucleoside reverse transcriptase inhibitor (NNRTI) class, efavirenz is an integral component of antiretroviral therapy (ART) regimens. By selectively inhibiting the reverse transcriptase enzyme, an essential catalyst for transcribing viral RNA into DNA, efavirenz disrupts the replication process of the human immunodeficiency virus. This module discusses the indications, contraindications, mechanism of action, pharmacokinetics, dosing guidelines, adverse effects, and potential drug interactions associated with efavirenz while highlighting its role in combating HIV and providing clinicians with essential insights for optimal patient management. Objectives: Identify potential candidates for efavirenz-based HIV therapy based on clinical guidelines and patient profiles. Implement efavirenz therapy with appropriate dosing, emphasizing the importance of adherence and addressing concerns about adverse effects. Assess patients regularly for medication efficacy and any adverse reactions, focusing on viral load suppression and CD4 count improvement. Develop effective communication with patients about efavirenz therapy, addressing potential adverse effects, adherence, and expectations. Access free multiple choice questions on this topic.

The toxicity of this drug is generally relative to serum concentrations. Overdose is uncommon, and life-threatening sequelae from acute overdose are rare. There is no antidote available for efavirenz overdose. Short-term toxicity is usually transient and does not require treatment interruption.[18]

Treatment with efavirenz can significantly improve the quality of life of patients infected with HIV, but its efficacy heavily relies on patient adherence. The neurologic adverse effects associated with efavirenz cause some patients to discontinue therapy. An interprofessional team of healthcare providers must become actively involved in caring for their HIV-positive patients. Key members of the team include pharmacists, physicians, advanced practice practitioners, nurses, and social workers. Obstacles to successful ART include a lack of social support and the financial burden of therapy. Healthcare providers must provide counsel regarding methods of coping with these adverse effects and promote medication adherence. Identifying appropriate opportunities for members of each discipline to provide care and encouragement is crucial to successful ART.[19] There are several recommendations for healthcare providers to assist in increasing successful outcomes in patients diagnosed with HIV on ART.[20] These recommendations include the following: Monitoring of successful entry into HIV care is recommended for individuals diagnosed with HIV. Nursing staff can play a significant role in this function and report their findings to the clinical team. Entry into care, defined as a visit with an HIV care provider, has demonstrated correlations with improved survival. Providers should obtain self-reported adherence routinely. Healthcare providers should ask patients about their appointment adherence. Nursing staff can play a significant role here in assessing pharmacotherapy adherence. Pharmacy refill data is recommended for adherence monitoring if medication refills are not automatically sent to patients. Pharmacy refill data can help to confirm self-reported adherence. If the pharmacist notices irregular refill activity, they should respond immediately, contacting both the patient and the prescriber. If regimens have equivalent efficacy, switching treatment-experienced patients receiving complex or poorly tolerated regimens to simpler once-daily regimens is recommended. A higher tablet/capsule burden is associated with lower adherence. Discussing the patient's tablet/capsule burden can identify an opportunity to improve compliance. The pharmacist can advise on newer combination formulations that decrease tablet/capsule burden.

If regimens have equivalent efficacy, switching treatment-experienced patients receiving complex or poorly tolerated regimens to simpler once-daily regimens is recommended. A higher tablet/capsule burden is associated with lower adherence. Discussing the patient's tablet/capsule burden can identify an opportunity to improve compliance. The pharmacist can advise on newer combination formulations that decrease tablet/capsule burden. Individual one-on-one ART education is recommended. Counseling, skills-building, and education increase adherence rates, which are crucial to therapeutic success. Interprofessional education and counseling intervention approaches are recommended. Interprofessional teams can provide education regarding multiple factors that affect adherence. Case management is necessary to minimize the number of adherence barriers in people experiencing homelessness. Assistance in acquiring mental health and substance abuse treatment and housing accommodations can significantly improve outcomes. In summary, efavirenz therapy requires an interprofessional team approach, including all interprofessional healthcare team members collaborating across disciplines and engaging in open communication to achieve optimal patient outcomes.